USPTO Has Not Seen ‘Deluge’ Of Inconsistent Statements From Applicants

 
• By Brenda Sandburg

Agency did not intend to ‘strong-arm or threaten’ anyone in its duty to disclose notice, patent office legal advisors say. Applicants should assess whether information required by FDA on new method of manufacturing or different formulation impacts patentability.

Consistency
USPTO attorneys note patent information that must be consistent with submissions to the FDA • Source: Shutterstock

More from Legal & IP

More from Pink Sheet